Soft Mist Inhalers Market Report 2026

Soft Mist Inhalers Market Overview

• Soft Mist Inhalers market size has reached to $3.06 billion in 2025 • Expected to grow to $4.48 billion in 2030 at a compound annual growth rate (CAGR) of 7.9% • Growth Driver: Rise In Asthma Fueling The Growth Of The Market Due To Increasing Air Pollution Exposure • Market Trend: Strategic Collaborations and Technological Advancements Driving Growth in the Soft Mist Inhalers Market through Enhanced Accessibility and Efficiency • North America was the largest region in 2025.

What Is Covered Under Soft Mist Inhalers Market?

A soft mist inhaler (SMI) is an inhalation device that delivers medication as a slow-moving, long-lasting aerosol mist generated without propellants. It allows for better lung deposition and easier inhalation, making it especially beneficial for patients with limited inspiratory capacity. The main product types of soft mist inhalers are portable soft mist inhalers, and stationary soft mist inhalers. Portable soft mist inhalers refer to a type of inhalation device that delivers medication in the form of a fine mist for the treatment of respiratory conditions like asthma or chronic obstructive pulmonary disease (COPD). The various applications include asthma, chronic obstructive pulmonary disease (COPD), respiratory diseases, and others and are used by several end-users such as hospitals and clinics, home care settings, and others.

What Is The Soft Mist Inhalers Market Growth Forecast?

The soft mist inhalers market size is expected to see strong growth in the next few years. It will grow to $4.48 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to home-based respiratory treatment growth, innovation in inhaler design, rising pollution levels, increasing chronic respiratory diseases, expansion of outpatient care. Major trends in the forecast period include adoption of soft mist drug delivery technology, increasing demand for patient-friendly inhalers, rising use in asthma and copd management, growth of homecare respiratory devices, focus on improved drug deposition efficiency.

Global Soft Mist Inhalers Market Segmentation

1) By Product Type: Portable Soft Mist Inhalers, Stationary Soft Mist Inhalers 2) By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Respiratory Diseases, Other Applications 3) By End-User: Hospitals And Clinics, Home Care Settings, Other End-Users Subsegments: 1) By Portable Soft Mist Inhalers: Handheld Reusable Soft Mist Inhalers, Disposable Single-Use Soft Mist Inhalers, Compact Travel-Friendly Inhalers, Pediatric-Use Portable Soft Mist Inhalers 2) By Stationary Soft Mist Inhalers: Homecare-Use Stationary Inhalers, Hospital-Grade Soft Mist Inhalers, Long-Term Therapy Devices

What Is The Driver Of The Soft Mist Inhalers Market?

The rise in the incidence of asthma is expected to propel the growth of the soft mist inhalers market going forward. Asthma is a chronic respiratory condition that causes inflammation and narrowing of the airways, making breathing difficult. The rise in the incidence of asthma is primarily due to increasing exposure to air pollution, which exacerbates respiratory conditions and impairs lung function over time. Soft mist inhalers help manage asthma and other chronic obstructive pulmonary diseases by delivering a fine, slow-moving mist of medication directly to the lungs, improving drug deposition and respiratory relief with minimal coordination effort. For instance, in October 2024, according to the National Asthma Council, an Australia-based non-profit organization, in 2023, Australia recorded a total of 474 asthma-related deaths, comprising 325 females and 149 males. This figure is almost identical to the 473 asthma-related deaths reported in 2022, highlighting a consistent trend in asthma mortality over the two years. Therefore, the increasing incidence of asthma is driving growth in the soft mist inhalers industry.

Key Players In The Global Soft Mist Inhalers Market

Major companies operating in the soft mist inhalers market are Boehringer Ingelheim Pharma GmbH & Co. KG, AstraZeneca plc, GlaxoSmithKline plc, Novartis International AG, Teva Pharmaceutical Industries Ltd., Viatris Inc., Cipla Limited, Chiesi Farmaceutici S.p.A., Sunovion Pharmaceuticals Inc., Orion Corporation, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Almirall S.A., Sandoz International GmbH, Zydus Lifesciences Limited, Hikma Pharmaceuticals plc, Bial – Portela & Ca. S.A., Menarini Group, Sanofi S.A., Abbott Laboratories, Pfizer Inc., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited

Global Soft Mist Inhalers Market Trends and Insights

Major companies in the soft mist inhalers (SMIs) market are focusing on strategic partnership approaches to expand their market presence and enhance the accessibility of their products. The companies aim to leverage complementary strengths and gain a competitive edge in delivering innovative, patient-centric inhalation therapies by collaborating with research institutions, technology firms, and regional healthcare providers. For instance, in 2024, Merxin Ltd., a UK-based company specializing in the design and supply of generic and customized inhaler devices, partnered with OECHSLERhealth, a Germany-based manufacturer of medical devices, and launched the Soft Mist Inhalers (SMI) Powerhouse. This innovative initiative aims to accelerate market entry for drug developers. It includes a strategic partnership with OECHSLER Health, which combines its manufacturing and assembly expertise with Merxin’s proprietary SMI design. Together, they aim to set new industry standards in intellectual property protection, performance, reliability, speed, and cost-effectiveness.

What Are Latest Mergers And Acquisitions In The Soft Mist Inhalers Market?

In January 2024, Recipharm AB, a Sweden-based pharmaceutical company, collaborated with Medspray to expand the application of soft mist inhaler (SMI) technology beyond traditional respiratory therapies by developing soft mist nasal delivery devices for both single and combination drug products. This deal aligns with Recipharm’s strategy to innovate drug delivery solutions and broaden its offerings in advanced inhalation technologies. Medspray is a Netherlands-based company specializing in soft mist inhalers and spray delivery systems.

Regional Insights

North America was the largest region in the soft mist inhalers market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Soft Mist Inhalers Market?

The soft mist inhalers market consists of sales of respimat inhalers, tiotropium, and ipratropium. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Soft Mist Inhalers Market Report 2026?

The soft mist inhalers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the soft mist inhalers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.